Lack of association between the TNF-α promoter gene polymorphism and susceptibility to B-cell chronic lymphocytic leukaemia

被引:18
作者
Bogunia-Kubik, K
Mazur, G
Urbanowicz, I
Wróbel, T
Kuliczkowski, K
Wozniak, M
Lange, A
机构
[1] Polish Acad Sci, L Hirszfeld Inst Immunol & Expt Therapy, PL-53114 Wroclaw, Poland
[2] Wroclaw Med Univ, Dept Haematol Blood Neoplasms & Bone Marrow Trans, PL-50367 Wroclaw, Poland
[3] Wroclaw Med Univ, Dept Clin Chem, PL-50367 Wroclaw, Poland
[4] Natl Bone Marrow Donor Registry, Lower Silesian Ctr Cellular Transplantat, Wroclaw, Poland
关键词
D O I
10.1111/j.1744-313X.2005.00553.x
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
B-cell chronic lymphocytic leukaemia (B-CLL) is a lymphoproliferative disorder characterized by clonal expansion of B lymphocytes. The present study aimed to determine whether there is an association between the polymorphic features located within the promoter/enhancer region of tumour necrosis factor-alpha (TNFA) gene and susceptibility to B-CLL. TNFA (-308 G/A) promoter single nucleotide polymorphism (SNP) was determined by polymerase chain reaction with sequence-specific primers (PCR-SSP) using commercial oligonucleotides. No significant association was found between the distribution of TNFA alleles and B-CLL in Polish patients with B-CLL. Our single centre results were compared with other literature data and combined in a cumulative analysis employing the Mantel-Haenszel method. Among 183 B-CLL patients, 47 (26%) were carrying TNFA*2 allele and this allele was present in 98 out of 348 controls (28%). Also, the results of the Mantel-Haenszel test did not show a significant correlation [Mantel-Haenszel estimate of approximate relative risk (RMH) = 0.86, P = 0.294]. These results suggest that TNFA (-308) alleles are not involved in the predisposition to the development of B-CLL.
引用
收藏
页码:21 / 24
页数:4
相关论文
共 25 条
[1]  
BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
[2]  
2-V
[3]  
Bogunia-Kubik K, 2004, ARCH IMMUNOL THER EX, V52, P240
[4]   TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation [J].
Bogunia-Kubik, K ;
Polak, M ;
Lange, A .
BONE MARROW TRANSPLANTATION, 2003, 32 (06) :617-622
[5]  
BOGUNIAKUBIK K, 2005, FOCUS IMMUNOLOGY RES, pCH4
[6]  
Bojarska-Junak A, 2002, HAEMATOLOGICA, V87, P490
[7]   B-cell chronic lymphocytic leukemia: A bird of a different feather [J].
Caligaris-Cappio, F ;
Hamblin, TJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :399-408
[8]   Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [J].
Damle, RN ;
Wasil, T ;
Fais, F ;
Ghiotto, F ;
Valetto, A ;
Allen, SL ;
Buchbinder, A ;
Budman, D ;
Dittmar, K ;
Kolitz, J ;
Lichtman, SM ;
Schulman, P ;
Vinciguerra, VP ;
Rai, KR ;
Ferrarini, M ;
Chiorazzi, N .
BLOOD, 1999, 94 (06) :1840-1847
[9]   Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia [J].
Demeter, J ;
Porzsolt, F ;
Ramisch, S ;
Schmidt, D ;
Schmid, M ;
Messer, G .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (01) :107-112
[10]   Genomic aberrations and survival in chronic lymphocytic leukemia. [J].
Döhner, H ;
Stilgenbauer, S ;
Benner, A ;
Leupolt, E ;
Kröber, A ;
Bullinger, L ;
Döhner, K ;
Bentz, M ;
Lichter, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) :1910-1916